Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...
PHILADELPHIA -- Pfizer and BioNTech said Tuesday they have submitted Covid-19 vaccine data on children ages 5 to 11 to the US Food and Drug Administration for initial review, but are not yet seeking ...
VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...
Pfizer (PFE) stock and Arvinas (ARVN) stock are in focus as the FDA approves the companies' breast cancer drug, Veppanu. Read ...
NEW YORK, N.Y. — Pfizer and BioNTech announced Friday that they’re submitting new data to the Food and Drug Administration (FDA) that shows their COVID-19 vaccine can be stored at higher temperatures, ...
Pfizer and Astellas have received the US Food and Drug Administration (FDA) acceptance for priority review of their ...
Pfizer’s multiple myeloma drug Elrexfio met its main goal in a late-stage trial, delivering a statistically significant and clinically meaningful improvement in progression-free survival over standard ...
Pfizer on Monday announced it submitted data to the Food and Drug Administration regarding the results of Phase 1 trials for a potential COVID-19 vaccine booster shot. In a press release, Pfizer said ...
April 29 () - Pfizer said on Wednesday its drug Elrexfio met the main goal in a late-stage trial that tested the blood ...
NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results